Pier Capital, LLC Anavex Life Sciences Corp. Transaction History

Pier Capital, LLC

$613 Million
Q2 2025

A detailed history of Pier Capital, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Pier Capital, LLC holds 424,148 shares of AVXL stock, worth $4.57 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares

424,148

Previous 455,427 6.87%

Holding current value

$4.57 Million

Previous $3.91 Million 0.08%

% of portfolio

0.64%

Previous 0.69%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 04, 2025	SELL	$7.37 - $9.63 $230,526 - $301,216	-31,279 Reduced 6.87%	424,148 $3.91 Million
Q1 2025 May 13, 2025	BUY	$7.85 - $13.46 $106,069 - $181,871	13,512 Added 3.06%	455,427 $3.91 Million
Q4 2024 Feb 11, 2025	BUY	$5.11 - $12.56 $2.26 Million - $5.55 Million	441,915 New	441,915 $4.75 Million
Q4 2022 Feb 15, 2023	SELL	$7.65 - $14.43 $795,271 - $1.5 Million	-103,957 Reduced 27.02%	280,854 $2.6 Million
Q3 2022 Nov 15, 2022	BUY	$8.9 - $12.86 $5,624 - $8,127	632 Added 0.16%	384,811 $3.97 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $764,004 - $1.34 Million	-104,515 Reduced 21.39%	384,179 $3.85 Million
Q1 2022 May 10, 2022	BUY	$9.74 - $17.69 $2.07 Million - $3.76 Million	212,350 Added 76.84%	488,694 $6.02 Million
Q4 2021 Feb 10, 2022	BUY	$16.88 - $23.31 $2,717 - $3,752	161 Added 0.06%	276,344 $4.79 Million
Q3 2021 Nov 10, 2021	BUY	$16.82 - $25.75 $4.65 Million - $7.11 Million	276,183 New	276,183 $4.96 Million

Others Institutions Holding AVXL

# of Institutions

197

Shares Held

31.8M

Call Options Held

1.31M

Put Options Held

875K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $840M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier Capital, LLC with notifications on news.

Account